To support our bridge between the US and China markets and the launching of our clinical pipeline, we have numerous companies that are part of our family.
Comprehensive Drug Enterprises Ltd is a specialty pharmaceutical company that focuses on the development of transmucosal drug delivery, with special emphasis on sublingual and nasal administration of pharmaceuticals. CDE had patented a number of technologies through their research for their product development.
CDE was founded in 2005 and located at a research facility in Hong Kong Science Park and their new medical devices production facility in Chongqing was just established in July, 2014. CDE facilitated and grow rapidly in China, Hong Kong and Taiwan and their product market is estimated at about USD 760 million. CDE was teamed by a group of dedicated scientists and professionals with various disciplines associated with financing, sales and marketing, pharmaceutical research and development, and corporate management.
CDE leveraged by the local government support and an extensive research collaboration network with universities in Hong Kong, China and the US. CDE worked closely with their business partners in research and development. For example, the leader in nanotechnologies and advanced material, Nano and Advanced Materials Institute Limited (NAMI) is one of CDE major collaborators. The only sublingual Propranolol product in the market, Promptol™, which is for hypertension management and that had already secured a US patent on “Method of Enhancing Absorptions of Transmucosal Administration Formulations”.
The invention of Promptol™ brought CDE a Technological Achievement Award from HK Awards for Industries in 2007. In 2012, CDE launched a motion sickness oral solution, Averti™ and it had registered successfully in Hong Kong in the same year. A new product of CDE in Anti-itching, Antipruritic Hydrogel had been approved by China Government on Registration of Drug and it can be sold to the market in China already. CDE has many more products to be launched in 2014–2015 and they are prepared to compete in the US market within the next two years.
Based in U.S.A., Polymed Therapeutics has been at the forefront in the manufacture of APIs and Chemicals, with state-of-the-art and regulatory approved cGMP facilities and R&D laboratories in China.
For the past decade our API division has been a leader in the supply of pharmaceutical grade yet low cost specialty active ingredients and intermediates, for the global market. Our product portfolio has since expanded from Paclitaxel to more oncology APIs, Vitamin D analogues, plus other categories.
Our Fine Chemicals division specializes in Custom Synthesis, and serves the global markets of Pharmaceutical and Specialty Chemicals. Our team of scientists is expert in the whole range of manufacture – from R&D, pilot scale, to industrial scale. Being flexible and fast, our plants achieve extremely complex or simple synthesis, for large or small demands.
Our in-vitro diagnostic devices are rapid testing kits used to detect, prevent, and diagnose various medical conditions. These kits are simple to use and are priced competitively to meet our customers’ needs. Our scientific team of experts manufacture these high quality medical device kits. Polymed is a cGMP facility that meets the ISO standards.
Polymed is financially stable, technologically proficient and dedicated to providing the most excellent products and services at competitive costs, to be the optimal strategic supplier to global customers.
Founded in 2010, QuaDPharma, Inc. was designed from the beginning to serve the needs of the pharmaceutical industry that relates to small-scale pre-commercial and commercial manufacturing. It has synthesis expertise in Drug Discovery and Pilot Plant scale-up.